News >

High-Dose Cytarabine Induction Regimens Elicit High Responses in Transplant-Eligible MCL

Brittany Cote
Published: Monday, Mar 23, 2020

Reid W. Merryman, MD, instructor of medicine, Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute

Reid W. Merryman, MD

The addition of high-dose cytarabine to bendamustine and rituximab (Rituxan; BR) or rituximab were found to generate high response rates for transplant-eligible patients with mantle cell lymphoma (MCL), according to results of a pooled analysis that were published in Blood Advances.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication